Nebivolol
<languages /> <translate>
Information about Nebivolol[edit]
Nebivolol is a beta-blocker and antihypertensive medication that has additional vasodilatory activity mediated by nitric oxide release.
Liver safety of Nebivolol[edit]
Nebivolol has yet to be linked to instances of clinically apparent liver injury.
Mechanism of action of Nebivolol[edit]
Nebivolol (ne biv' oh lol) is an antihypertensive agent that has both beta-adrenergic receptor blocking activity and separate direct vasodilatory actions. The beta blockade is cardioselective, acting largely on beta-1 adrenergic receptors. Beta-1 adrenergic blockade reduces the heart rate and myocardial contractility by slowing the atrioventricular (AV) conduction and suppressing automaticity. Nebivolol also has vasodilatory activity that is not explained by typical beta blockade and appears to be mediated by release of nitric oxide from endothelial cells.
FDA approval information for Nebivolol[edit]
Nebivolol was approved for use in the United States in 2007 and it is currently indicated for the management of hypertension either as monotherapy or in combination with other antihypertensive agents.
FDA approval information for Nebivolol[edit]
Nebivolol is available in tablets of 2.5, 5, 10 and 20 mg under the trade name Bystolic. The typical initial oral dose in adults is 5 mg once daily, with subsequent dose modification based upon clinical response and tolerance; the total daily maintenance dose ranges from 5 to 40 mg.
Side effects of Nebivolol[edit]
Common side effects of nebivolol include bradycardia, hypotension, fatigue, dizziness, depression, memory loss, incontinence, cold limbs and, less commonly, severe hypotension, heart failure and bronchospasm. Sudden withdrawal can trigger rebound hypertension.
| Beta blockers (C07) | ||||||||
|---|---|---|---|---|---|---|---|---|
|
</translate>
